This report is no longer available. Click here to view our current reports or contact us to discuss a custom report.
If you have previously purchased this report then please use the download links on the right to download the files.
1. | EXECUTIVE SUMMARY |
1.1. | The Scope of Synthetic Biology is Vast |
1.2. | Important Societal, Economic and Environmental Factors |
1.3. | Drivers and Barriers for Adoption of Synthetic Biology |
1.4. | The Global Differences in Regulation for Genetic Engineering |
1.5. | 2018 is Set to Be Another Record-Breaking Year |
1.6. | Key Applications |
1.7. | Key Players in Organism Engineering |
1.8. | The Outlook for Synthetic Biology in Organism Engineering |
1.9. | Key Players in Food and Agriculture |
1.10. | The Outlook for Synthetic Biology in Food and Agriculture |
1.11. | Key Players in Materials and Consumer Products |
1.12. | The Outlook for Synthetic Biology in Engineering Materials |
1.13. | Key Players in Specialty Chemicals |
1.14. | The Outlook for Synthetic Biology in Specialty Chemicals |
1.15. | The Range of Biobased Monomers |
1.16. | A Rapidly Growing but Uncertain Technology |
1.17. | Suppliers of PHAs |
1.18. | Applications and Opportunities for PHAs |
1.19. | Suppliers of Lactide and Poly(lactide) |
1.20. | Current and Future Applications of Poly(lactide) |
1.21. | Biobased Polyester Suppliers |
1.22. | Key Players in Human Therapeutics |
1.23. | The Outlook for Synthetic Biology in Human Therapeutics |
1.24. | Synthetic Biology Funding Continues to Increase |
1.25. | Investment Forecast 2018 - 2023 |
2. | INTRODUCTION |
2.1. | The Design and Engineering of Biological Systems |
2.2. | Manipulating the Central Dogma |
2.3. | The Scope of Synthetic Biology is Vast |
2.4. | Important Societal, Economic and Environmental Factors |
2.5. | The Process of Synthetic Biology: Design, Build and Test |
2.6. | Cell Factories for Biomanufacturing: A Range of Organisms |
2.7. | Technological Advances Resulting from Synthetic Biology |
2.8. | Why Now for Synthetic Biology? |
2.9. | From Pharmaceuticals to Consumer Products |
2.10. | Disruption of Existing Supply Chains |
2.11. | Drivers and Barriers for Adoption of Synthetic Biology |
3. | TOOLS AND TECHNIQUES |
3.1.1. | Outline |
3.1.2. | The Techniques and Tools of Synthetic Biology |
3.1.3. | DNA Synthesis |
3.1.4. | Applications for DNA Synthesis |
3.1.5. | Twist Bioscience |
3.1.6. | Gene Editing |
3.2. | CRISPR-Cas9 |
3.2.1. | What Exactly is CRISPR-Cas9? |
3.2.2. | CRISPR-Cas9: A Bacterial Immune System |
3.2.3. | Why is CRISPR-Cas9 so Important for Synthetic Biology? |
3.2.4. | Who Owns CRISPR-Cas9 and Why is it so Problematic? |
3.2.5. | An Update on the Ongoing Patent Battle |
3.2.6. | Commercializing CRISPR-Cas9 |
3.2.7. | Licensing Agreements with Commercial Enterprises |
3.2.8. | Companies are Finding Ways of Avoiding Royalties |
3.2.9. | Products Engineered Using CRISPR-Cas9 |
3.2.10. | Clinical Trials Testing CRISPR-Cas9 in Humans Have Started |
3.2.11. | Alternatives to CRISPR-Cas9 Exist |
3.2.12. | The Outlook for CRISPR-Cas9 |
3.3. | Protein Engineering |
3.3.1. | Protein/Enzyme Engineering |
3.3.2. | Computer-Aided Design |
3.3.3. | Commercial Examples of Engineered Proteins |
3.3.4. | Strain Construction and Optimization |
3.3.5. | Framework for Developing Industrial Microbial Strains |
3.3.6. | The Problem with Scale |
3.3.7. | Commercial Examples of Strain Development |
3.3.8. | Cell-Free Systems |
3.3.9. | Cell-Free versus Cell-Based Systems |
3.3.10. | Robotics: Enabling Hands-Free and High-Throughput Science |
3.3.11. | Robotic Cloud Laboratories |
3.3.12. | Automating Organism Design and Closing the Loop |
3.3.13. | Artificial Intelligence and Machine Learning |
4. | APPLICATIONS |
4.1. | Organism Engineering |
4.1.1. | Key Players in Organism Engineering |
4.1.2. | Ginkgo Bioworks |
4.1.3. | Ginkgo's Automated Approach to Strain Engineering |
4.1.4. | Zymergen |
4.1.5. | DEINOVE |
4.1.6. | Arzeda |
4.1.7. | Arzeda: Computational Design, HTS and Data Science |
4.1.8. | The Outlook for Synthetic Biology in Organism Engineering |
4.2. | Food and Agriculture |
4.2.1. | Key Players in Food and Agriculture |
4.2.2. | Perfect Day |
4.2.3. | Impossible Foods |
4.2.4. | Clara Foods |
4.2.5. | Geltor |
4.2.6. | MiraculeX |
4.2.7. | The Outlook for Synthetic Biology in Food and Agriculture |
4.3. | Materials and Consumer Products |
4.3.1. | Key Players in Materials and Consumer Products |
4.3.2. | Manufacturing Spider Silk |
4.3.3. | Applications for Spider Silk |
4.3.4. | Spider Silk Without Spiders |
4.3.5. | Bolt Threads |
4.3.6. | Spiber |
4.3.7. | Kraig Biocraft Laboratories |
4.3.8. | Modern Meadow |
4.3.9. | Biofabrication of Leather |
4.3.10. | A Competitor for Modern Meadow? |
4.4. | Specialty Chemicals |
4.4.1. | Key Players in Specialty Chemicals |
4.4.2. | Metabolic Explorer |
4.4.3. | Arzeda |
4.4.4. | Green Biologics |
4.4.5. | GreenLight Biosciences |
4.4.6. | Novozymes |
4.4.7. | The Outlook for Synthetic Biology in Specialty Chemicals |
4.5. | Biobased Polymers |
4.5.1. | The Range of Biobased Monomers |
4.5.2. | A Rapidly Growing but Uncertain Technology |
4.5.3. | Polyesters |
4.5.4. | Introduction to Poly(hydroxyalkanoates) |
4.5.5. | Suppliers of PHAs |
4.5.6. | PHAs: Microstructures and Properties |
4.5.7. | Biosynthetic Pathways to PHAs |
4.5.8. | Applications and Opportunities for PHAs |
4.5.9. | Polyesters |
4.5.10. | Introduction to Poly(lactide) |
4.5.11. | Optimal Lactic Acid Bacteria Strains for Fermentation |
4.5.12. | Engineering Yeast Strains for Lactic Acid Fermentation |
4.5.13. | Fermentation, Recovery and Purification |
4.5.14. | Suppliers of Lactide and Poly(lactide) |
4.5.15. | Current and Future Applications of Poly(lactide) |
4.5.16. | Other Biobased Polymers |
4.5.17. | The Range of Available Biobased Polyesters in 2018 |
4.5.18. | Biobased Polyester Suppliers |
4.6. | Human Therapeutics |
4.6.1. | Key Players in Human Therapeutics |
4.6.2. | Synthetic Biology in Human Therapeutics |
4.6.3. | Alternative Sources of Therapeutic Proteins |
4.6.4. | Changing the Microbiome as Therapy |
4.6.5. | Vedanta Biosciences |
4.6.6. | Gene and Cell Therapies |
4.6.7. | Spark Therapeutics |
4.6.8. | Chimeric Antigen Receptor T-Cell Therapy |
4.6.9. | CAR-T: Companies |
4.6.10. | Kite Pharma (Gilead Sciences) |
4.6.11. | The Outlook for Synthetic Biology in Human Therapeutics |
5. | REGULATION |
5.1. | Where Regulation is at Currently for Genetic Engineering |
5.2. | The Global Differences in Regulation for Genetic Engineering |
5.3. | Area of Genetically Engineered Crops by Country, 2016 |
5.4. | Regulation of Human Gene Editing Varies |
5.5. | Regulation of Gene and Cell Therapies |
5.6. | The Growing Concern of Biosecurity |
5.7. | Policing Synthetic Biology |
5.8. | Genetically Modified Organisms is NOT the Correct Term |
5.9. | Learning Lessons from the Past: Golden Rice |
5.10. | Impact on Economies, and Changing Opinions |
5.11. | To GM, or not to GM...That is the Question |
6. | INVESTMENT IN SYNTHETIC BIOLOGY |
6.1. | Synthetic Biology Funding Continues to Increase |
6.2. | Synthetic Biology Companies Attracted $1.7B Funding in 2017 |
6.3. | 2018 is Set to Be Another Record-Breaking Year |
6.4. | Turning Synthetic Biology into a Global Enterprise |
6.5. | Investment Forecast 2018 - 2023 |
7. | APPENDIX |
7.1. | Common Definitions & Acronyms in Synthetic Biology |
7.2. | List of Abbreviations |
Slides | 178 |
---|---|
Forecasts to | 2023 |